All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On March 20, 2024, the European Commission granted approval to idecabtagene vicleucel (ide-cel) for the treatment of triple-class-exposed relapsed/refractory multiple myeloma (RRMM) with two or more prior therapies, including an immunomodulatory agent (IMiD), proteasome inhibitor (PI), and an anti-CD38 antibody with subsequent disease progression.1
In August, 2021, ide-cel was granted approval by the European Commission for the treatment of RRMM treated with three or more prior therapies, including an IMiD, PI, and anti-CD38 monoclonal antibody.2 This latest approval for ide-cel marks the first chimeric antigen receptor (CAR) T-cell therapy approved in earlier lines of therapy. This approval is based on data from the phase III KarMMa-3 (NCT03651128) clinical trial.1
The Multiple Myeloma Hub has previously reported the study design of KarMMa-3 and latest updates from ASH 2023.
Figure 1. Incidence of CRS and neurotoxicity*
CRS, cytokine release syndrome.
*Data from Bristol Myers Squibb.1
Subscribe to get the best content related to multiple myeloma delivered to your inbox